Latest news with #ScientificAdvisoryBoard
Yahoo
4 days ago
- Business
- Yahoo
Dr. James Y. Wang Joins Epicutis as Chairman of the Scientific Advisory Board
Harvard-Trained Dermatologist Brings Expertise to Biotech Skin Health Brand IRVINE, Calif., June 18, 2025 /PRNewswire/ -- Epicutis, a pioneering biotech skincare brand known for its science-backed, clean formulations that prioritize skin health over beauty, proudly announces the appointment of Dr. James Y. Wang as Chairman of its Scientific Advisory Board. As a Harvard and UCLA-trained double board-certified dermatologist and dermatopathologist, Dr. Wang brings a wealth of expertise in medical and aesthetic dermatology, reinforcing Epicutis' mission to deliver clinically advanced, non-toxic skincare solutions to market. James Y. Wang, MD, Founder of Metropolis Dermatology, with five locations in California, is widely recognized as a leader in dermatology, specializing in the diagnosis and treatment of skin cancers, psoriasis, eczema, and acne. His impressive academic background includes graduating summa cum laude and Phi Beta Kappa in biology from Washington University in St. Louis, followed by earning his MD from Harvard Medical School and an MBA in healthcare policy from Harvard Business School. "As a physician, I am committed to evidence-based skincare that is not only safe for all skin types but also effective," shares Dr. Wang. "Epicutis represents the perfect fusion of biotechnology and dermatological science, delivering formulations that truly transform skin health at a cellular level, and I am honored to contribute to this next chapter of innovation." Epicutis was founded on the principles of biotech-driven skincare, leveraging the research of Dr. Jeffrey Stock, a distinguished biophysicist and Princeton University professor. By harnessing proprietary, patented active ingredients, Epicutis formulates small-batch, high-performance skincare products available exclusively through skin professionals. With a focus on transparency, efficacy, and the elimination of unnecessary additives and stabilizers, the brand continues to set new standards in professional skincare. "We are thrilled to have Dr. Wang join us as Chairman of our Scientific Advisory Board," said Maxwell Stock, Founder and CEO of Epicutis. "His deep understanding of dermatological science and passion for cutting-edge innovation align perfectly with our mission to clean up the skincare industry and support clinicians with science-backed, 100% non-toxic products that make a true impact on skin health." With Dr. Wang's leadership, Epicutis is advancing its commitment to safe, biotech-driven skincare solutions while championing higher regulation to ensure safety and efficacy in an industry often dominated by misleading marketing and mass production. By prioritizing science-backed formulations with patented, highly concentrated therapeutic ingredients, Epicutis is empowering skincare professionals to stand a chance against big beauty. More than just providing innovative products – the brand is actively investing in its partners' success, helping aesthetic businesses grow with exclusive, clinical-grade solutions that drive real results and build lasting patient trust. For more information on Epicutis and its revolutionary approach to skincare, visit About EpicutisEpicutis is a science-based, luxury professional skincare line that treats skin health and not age. Honoring a commitment to clean beauty and fewer ingredients, Epicutis offers science-based skincare using patented active ingredients in small-batch formulations created by expert formulator Masanori Tamura. Epicutis' novel ingredients are developed in-house by a team of scientists at Signum Biosciences utilizing technology discovered by Dr. Jeffry Stock at Princeton University. Signum Biosciences is a biopharmaceutical company focused on the discovery and development of innovative products to address major consumer and medical needs, and the development of compounds and botanical extracts that are mimetics of natural lipid ligands crucial to cellular regulation and signaling. To learn more about Epicutis, visit To learn more about Signum Biosciences, visit View original content to download multimedia: SOURCE Epicutis Skincare Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical research in cancer biology, genomics, and Shaknovich currently serves as Chief Medical Officer at Agilent Technologies, where she oversees medical strategy and contributes to the development of innovative diagnostic solutions. Prior to joining Agilent, Dr. Shaknovich held senior leadership positions at GRAIL and Cancer Genetics, where she played pivotal roles in clinical and translational initiatives. She began her career in academic medicine, serving as Assistant Professor at Weill Cornell Medical College and Montefiore Medical Center (NY). "We are honored to welcome Dr. Shaknovich to our Scientific Advisory Board," said Dr. Patrizia Paterlini, CEO and Founder of Rarecells, Inc. "Her extensive expertise in molecular pathology and her commitment to advancing cancer diagnostics align perfectly with Rarecells' mission to revolutionize early cancer detection through innovative liquid biopsy technologies." Rarecells, Inc. is renowned for its ISET® (Isolation by SizE of Tumor cells) technology, a cutting-edge approach that enables the detection of circulating tumor cells (CTCs) and CTC-DNA in the bloodstream, facilitating early cancer diagnosis and monitoring. The addition of Dr. Shaknovich to the Scientific Advisory Board underscores the company's dedication to integrating top-tier scientific insights into its research and development efforts. "I am excited to join Rarecells' Scientific Advisory Board and contribute to their groundbreaking work in liquid biopsy," said Dr. Shaknovich. "Early detection is crucial in the fight against cancer, and I look forward to collaborating with the team to advance technologies that can significantly impact patient outcomes." About Rarecells, Inc. Rarecells, Inc. is a leading company in the development of innovative non-invasive tests for early cancer diagnosis based on the proprietary hypersensitive approaches of combined CTC-DNA, ctDNA molecular detection and AI-based Circulating Tumor Cells (CTCs) identification. Founded in 2012, the firm is headquartered in New York with offices and laboratories in New York and Paris. For more information, visit A photo accompanying this announcement is available at CONTACT: Contact: media@
Yahoo
06-06-2025
- Health
- Yahoo
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo's CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) - SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced the formation of its neuroscience-focused Scientific Advisory Board (SAB) comprised of distinguished experts in the field. The SAB will be chaired by Charles B. Nemeroff, M.D., Ph.D., Chair and Professor of the Department of Psychiatry and Behavioral Sciences at Dell Medical School at The University of Texas at Austin. Dr. Nemeroff served as president of the American College of Psychiatrists and the American College of Neuropsychopharmacology, and is past-president of the Anxiety and Depression Association of America (ADAA). 'We are extremely honored to welcome such a distinguished group of scientific leaders to join our efforts at Denovo Biopharma as we work towards addressing a major unmet need in the psychiatry field with a novel precision medicine,' said Wen Luo, Ph.D., Chief Executive Officer of Denovo Biopharma. 'As we prepare our lead asset, DB104, to enter a biomarker-guided Phase 3 study in TRD, we believe their guidance will be instrumental in shaping both our clinical development strategy and our regulatory path forward. We are thankful for their support and look forward to collaborating as we work to advance a first-in-class, potentially transformative therapy for patients with TRD.' Other members of Denovo's neuroscience Scientific Advisory Board include: Stephen Brannan, M.D., is a neuroscience drug development expert with over 15 years of industry experience. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he was instrumental in the development of CobenfyTM for the treatment of schizophrenia, which was later acquired by Bristol Myers Squibb for $14 billion. Prior to Karuna, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta®, Exelon Patch®, Trintellix®, and Vagal Nerve Stimulation for TRD during his tenures at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. Sanjay Mathew, M.D., is Professor of Psychiatry and Behavioral Sciences, Director of Mood and Anxiety Disorders Program, and Vice Chair for Research at Baylor College of Medicine. He is currently ADAA's President-Elect and Chief Medical Officer. Dr. Mathew is a leading expert in the areas of experimental therapeutics and pathophysiology of TRD, suicide, and PTSD. About DB104 (biomarker-guided liafensine) Liafensine is a first-in-class triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine. It was licensed from Albany Molecular Research, Inc. (now Curia) and was previously developed by Bristol-Myers Squibb (BMS), who had conducted two large Phase 2b clinical trials in non-selected TRD patient population. Denovo's unique artificial intelligence (AI) and whole genome sequencing (WGS)-based Denovo Genomic Marker (DGM™) biomarker platform allowed discovery of a novel genetic biomarker at the ANK3 gene, with a strong correlation of ANK3-positive status with liafensine's efficacy in the BMS studies. Denovo's ENLIGHTEN Phase 2b study results prospectively demonstrated the use of ANK3 as a predictive biomarker for liafensine's efficacy in TRD patients, a first for genetic biomarkers in psychiatry. About Denovo Biopharma Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that uses novel biomarker approaches to execute efficient clinical trials in targeted patient subpopulations to increase the probability of success. Denovo has seven late-stage drugs in its pipeline addressing major unmet medical needs in central nervous system diseases and oncology, most of which are first in class drugs with global rights. Visit for additional information. Investor Contact: Stephen Jasper Gilmartin Group stephen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Business
- Yahoo
Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit's BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit's Scientific Advisory Board alongside Commit's CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the Scientific Advisory Board AARHUS, Denmark, June 4, 2025 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat autoimmune disease and cancer, today announces the formation of its Scientific Advisory Board (SAB) with the appointment of five leading industry and scientific experts. The newly formed board will be co-chaired by leading antibody expert Janine Schuurman, PhD, and Commit's CEO Mikkel Wandahl Pedersen. They are being joined by Professor of Molecular Immunology, former Genmab SVP and serial biotech entrepreneur Paul Parren, PhD; former Regeneron SVP of Oncology Research Gavin Thurston, PhD; esteemed immunologist Susan Kalled, PhD, who has previously worked as CSO at both Dianthus Therapeutics and Compass Therapeutics; and molecular biologist Esper Boel, PhD, previously CTO at Symphogen and Corporate Vice President and Head of Biotechnology at Novo Nordisk. The SAB will provide constructive feedback to Commit's management team and Board of Directors as the Company further develops its Bispecific Complement Engager (BiCE™) technology platform. Mikkel Wandal Pedersen, PhD, Chief Executive Officer of Commit Biologics, said: "Forming Commit's Scientific Advisory Board is a pivotal step in our mission to bring first-in-class complement engager therapeutics to patients. I am very pleased that we have been able to gather such an accomplished group of people with deep immunology and drug-development experience. I am confident that their collective insight will sharpen our strategy and accelerate advancement of our pipeline." Scientific Advisory Board Janine Schuurman, PhD, is a molecular immunologist who has contributed to six FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab's DuoBody bispecific antibody platform. She spent 22 years at Genmab, most recently as Senior Vice President, Head of Antibody Research and Technology, propelling the discovery and development of investigational therapies to treat cancer and other diseases. Besides serving as an independent biotech consultant providing expert advice to a number of life sciences companies, Janine also serves as board member and President of The Antibody Society. Gavin Thurston, PhD, is a highly experienced R&D executive and scientific leader with over 20 years of experience in oncology research. He previously served as Senior Vice President of Oncology Research at Regeneron, where he played a pivotal role in the successful clinical development of LIBTAYO® and the ongoing late-stage clinical testing of seven other antibodies and bispecific antibodies. Following his time at Regeneron, Dr Thurston has been involved in a number of consultancy projects with antibody therapeutic companies. Paul Parren, PhD, is a molecular immunologist who has contributed to nine FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab's DuoBody bispecific antibody platform. He has spent over 25 years translating antibody knowledge into innovative therapies including 15 years at Genmab, where he headed preclinical R&D. More recently he was head of R&D at LAVA Therapeutics NV, which obtained a NASDAQ listing during his five-year tenure. He currently serves as Professor of Molecular Immunology at Leiden University Medical Centre in The Netherlands, is chairman of the board of The Antibody Society, provides expert advice and is a co-founder and CSO of Gyes BV and its two spin-out companies. Susan Kalled, PhD, is an immunologist with over 25 years of experience spanning early discovery research, clinical drug development and strategic partnerships in the areas of autoimmunity & inflammation, rare diseases and immuno-oncology. Previously she was CSO at Dianthus Therapeutics and Compass Therapeutics. As Vice President of Biology at Q32 Bio, Kalled established the founding research team and played a key role in shaping the company's complement and immunology-focused pipeline. She has also held a number of leadership positions at Biogen and Shire, driving scientific strategy. She currently serves as a scientific strategist and advisor to both early start-ups and established companies. Esper Boel, PhD, is a molecular biologist with 40 years of experience in international biopharmaceutical R&D. He spent 34 years at Novo Nordisk, most recently as Corporate Vice President and Head of Biotechnology. During this time, he was responsible for building and heading a 240+ employee international protein-biotechnology organisation and he established the first international biopharmaceutical R&D centre in Beijing, China. Following his time at Novo Nordisk, he has served as a member of executive teams, on boards and as a senior advisor for a number of high-profile immunology-based companies. Commit Biologics is advancing development of its BiCE™ technology to redefine the treatment of autoimmune disease and cancer. This novel platform is designed to potently activate the complement system to induce highly selective killing of cells implicated in autoimmune disease or tumour cells. BiCE™ uses single domain antibodies that bind to the complement protein C1q, consequently directing the complement system in a highly targeted way against cells of interest. The complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defence, begins with the engagement of C1q to antibodies that coat the cell surface, thus initiating multiple effector functions that lead to cell killing. About Commit BiologicsCommit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in autoimmune diseases and cancer. Spun out of Aarhus University, and building on more than three decades of research, Commit's Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumour-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body's natural immune system that leverages both the direct cytolytic activity of complement along with its ability to recruit and activate both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Novo Holdings, Bioqube Ventures and Korys. About the complement systemThe complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defence, begins with the engagement of C1q to antibodies that coat the cell surface and ends with the activation of a cytolytic complement complex directly leading to cell lysis. However, current monoclonal antibodies developed for therapeutic purposes have structural restraints that hinder effective engagement to C1q, thus limiting complement mediated cytotoxicity and other complement mediated effector functions. This, plus the presence of natural cell bound complement inhibitors that are often upregulated in disease settings, and low target densities, make conventional therapeutic antibodies poor complement activators. Commit's BiCE™ technology was developed to overcome these barriers, to harness the power of the complement system and direct it towards tumour and immune cells for therapeutic applications. Unleashing this power in a highly targeted way with Commit's technology potentially allows for a broad therapeutic index and the development of highly effective treatments. View original content: SOURCE Commit Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Health
- Yahoo
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
LOS ANGELES, May 21, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation ('Trethera'), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will assist in evaluating the clinical development of Trethera's lead asset, TRE-515, in demyelinating autoimmune diseases. A demyelinating disease is any condition that causes damage to the protective covering (myelin sheath) that surrounds nerve fibers. When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems. Dr. Greenberg is an internationally recognized neurologist specializing in rare autoimmune disorders of the central nervous system. He currently serves as Vice Chair of Clinical and Translational Research and Professor of Neurology and Pediatrics at UT Southwestern Medical Center. Dr. Greenberg completed his medical degree at Baylor College of Medicine, followed by an internal medicine internship at Rush–St. Luke's Presbyterian Hospital and a neurology residency at Johns Hopkins Hospital, where he later served as co-director of the Transverse Myelitis Center. Since joining UT Southwestern in 2009, he has founded multiple pioneering programs, including the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program. 'It's fantastic to have Dr. Greenberg join our team,' said Immunology Advisory Board Chairman Dr. Peter M. Clark of UCLA. 'With his addition, we now have an exceptional and purpose-driven team at Trethera with the world's foremost experts from Harvard, Stanford, and UT Southwestern to provide scientific answers as well as enroll patients in our forthcoming neuroimmunology Phase 1 clinical trials to transform patient care.' 'I'm honored to have Dr. Greenberg join the Scientific Advisory Board and support the advancement of TRE-515 as a potential treatment for patients with rare demyelinating diseases,' said Dr. Ken Schultz, Chairman and CEO of Trethera. 'Safe and effective treatments for these neurologic conditions represent a significant unmet need, particularly in pediatric populations, where existing therapies often carry substantial side effects and deliver inconsistent results.' Dr. Greenberg's research and clinical expertise focus on demyelinating and inflammatory disorders such as acute disseminated encephalomyelitis (ADEM), optic neuritis, neuromyelitis optica spectrum disorder (NMOSD), and transverse myelitis. As the principal investigator of major national collaborative studies, he has contributed extensively to the discovery of novel biomarkers and the development of biorepository protocols that support precision diagnostics and treatment strategies. Dr. Greenberg's appointment to the Scientific Advisory Board further strengthens Trethera's commitment to advancing innovative therapies for autoimmune neurologic diseases. Trethera's clinical stage and first-in-class drug, TRE-515, holds FDA Orphan Drug status for both optic neuritis and ADEM. FDA Orphan Drug designation confers substantial advantages, including a faster path to market approval, FDA assistance in designing clinical trials, exemption from the $4M drug approval application fee, and eligibility for seven years of marketing exclusivity. Should the FDA approve TRE-515 for commercial use in ADEM, Trethera would be eligible for a pediatric priority review voucher. TRE-515 is currently being evaluated in a Phase 1 dose escalation solid tumors clinical trial. ADEM is an autoimmune disease, affecting 15,000 patients a year in the United States, with most cases occurring in six to eight year-old children. ADEM can present with fever and difficulty walking that progresses to loss of consciousness, coma, and even death. Optic neuritis typically occurs in adult patients, manifesting with rapid vision loss in one or both eyes, with up to one in four patients never fully recovering their eyesight. Over 100,000 cases of optic neuritis occur annually in the US and have a close association with multiple sclerosis (MS). Figure 1: Representative stained sections of the optic nerve from mice experiencing optic neuritis. Arrows point to regions of leukocyte infiltration. Sources: Cleveland Clinic 2021; Bennett 2019; Yang 2017; Wilhelm 2015 About Trethera Trethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients. For more information, please visit us at or e-mail Investor Relations at ir@ You can also follow Trethera on Facebook and LinkedIn. Note on Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are 'forward-looking statements,' which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera's control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. A photo accompanying this announcement is available at in to access your portfolio
